

My experiences with external funding bodies in 4 quotes

Bruno Levecke

4 quotes

- Best deals are made in the pub
- Dance with me to the end of love
- Sharing is caring
- Be a DJ (in budget)

Overview

- What is my field of expertise?




Neglected Tropical Diseases - NTDs

Top 5 NTDS

- Soil-transmitted helminthiasis
- Schistosomiasis
- Lymphatic filariasis
- Dengue
- Onchocerciasis

Global Health Metrics

 Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016


 GRD 2016 DALYs and HALE Collaborators*

Countries dispensing preventive drugs for a selection of neglected tropical diseases*

By number of diseases, 2015

1
 2
 3
 4
 5

 No drugs required
 No data



*Lymphatic filariasis, river blindness, schistosomiasis, soil-transmitted helminthiases, trachoma

Countries that have eliminated:


- river blindness, 2013-16
- lymphatic filariasis, 2016-Apr 2017

The only countries with cases of guinea-worm disease in 2016

Source: WHO

Overview

- Who is funding my research?



Overview

- Experiences with funding bodies


Global Grand Challenges BILL & MELINDA GATES foundation

ABOUT PARTNERSHIPS **CHALLENGES** AWARDED GRANTS GRANT OPPORTUNITIES NEWS

CHALLENGES

Grand Challenges is a family of initiatives fostering innovation to solve key global health and development problems. Each initiative is an experiment in the use of challenges to focus innovation on making an impact. Individual challenges address some of the same problems, but from differing perspectives.

TITLE # **MOST RECENT +** Results per page

 **Balance the Equation - A Grand Challenge for Algebra 1**
Oct 7, 2020
Grand Challenges

Filter By Initiative (30)

Filter By Challenge (99)

Filter By Open Date (34)

0 / 5

- Bad project?
- Small player?
- Non-USA?



1 / 1



WHO Collaborating Centre for
Monitoring of Anthelmintic Drug Efficacy
for Soil-Transmitted Helminthiasis



Jozef Vercruyse
Ghent University



Julie Jacobson
Senior Program Officer @
B&MGF



Dirk Engels
Director NTDs @ WHO

June 2014

Control of STH - How to prevail against the challenges

Concept Note: How to prevail against the challenges of STH control?

Background
Up to date, mass drug administration (MDA) programmes, in which a single-oral dose of albendazole (ALB) or mebendazole (MEB) the drugs of choice for STHs are periodically administered to preschool-age and school-age children, are the main strategy to control the morbidity caused by STH and these programmes have recently received increased political and scientific attention. The World Health Organization (WHO) has devised a roadmap to guide implementation of the policies and strategies set out in a global plan to combat NTDs (period 2009-2015), and more than 70 pharmaceutical companies, governments, and global health organizations committed to supporting this roadmap in the London Declaration on NTDs in January 2012 by sustaining or expanding drug donation programmes. Currently, the priority for STH control is to increase the coverage of the preschool-age and school-age children in need of drug administration from the current 30% to at least 75% by 2020.

Objectives of the Bill and Melinda Gates Foundation (BMGF)
The Bill and Melinda Gates Foundation (BMGF) has the long term vision of breaking transmission of STH infections. The STH five-year strategic goals of the BMGF are:

- The demonstration the proof of concept that transmission can be broken in an area of on-going transmission
- The identification of feasible strategies for elimination and their contextual requirements

The STH field study objectives of the BMGF are:

- The demonstration of a clear "win" eliminating transmission through use of existing tools by 2020
- The identification of other feasible treatment scenarios and setting-up their use

Challenges
Beyond the objectives of BMGF there are three important challenges that need prioritization to guarantee a successful control and elimination of STH:
(1) Increasing the availability of alternative anthelmintic drug and/or drug combinations for STH control
(2) The set-up of surveillance systems to monitor the efficacy of the benzimidazole drugs

In the proposed activity section we will discuss these challenges more in detail and provide concrete suggestions on how these challenges can be prevailed.

- Mutually agreement on content
- Negotiating on budget
- Politics between partners
- Change in program officers

November 2015

BILL & MELINDA GATES foundation

GRANT AGREEMENT
November 12, 2015

AGREEMENT SUMMARY & SIGNATURE PAGE

GRANT INFORMATION	<p>Title: STH Control</p> <p>The Title: Globalization of MDA in a public administration setting in transmission threat</p> <p>You confirm that the above information is correct and agree to notify the Foundation immediately of any change.</p> <p>Grant Period: November 12, 2015 - December 31, 2015</p> <p>Grant Amount: \$1,000,000</p> <p>Grant Contact: Prof. Dr. P. Mordeir, Senior Program Officer, Respiratory Infectious Diseases, Johns Hopkins University, Baltimore, MD</p>
FOUNDATION INFORMATION	<p>Bill & Melinda Gates Foundation, 1000 L Street, N.E., Washington, DC 20002-4299, USA</p> <p>Grant Officer: Senior Program Officer, Respiratory Infectious Diseases, Johns Hopkins University, Baltimore, MD</p>
AGREEMENT INFORMATION	<p>Agreement and Extension of Terms to Strengthen Monitoring and Surveillance of Drug Delivery and Implementation Readiness in Sub-Saharan Africa (MDA-DRUG-IMPACT-DRUG)</p> <p>Charitable Purpose: To establish a global surveillance system that greatly monitors the efficacy of transmission, scale and spread of anthelmintic resistance in the transmission of STH programs</p> <p>Grant Period: November 12, 2015 - December 31, 2015</p> <p>Grant Amount and Reporting & Payment Schedule (Attachment A)</p> <p>Terms and Conditions (Attachment B)</p> <p>Proposed Narrative (last submitted October 16, 2014)</p> <p>Final Narrative and Final state submitted October 16, 2015</p> <p>Final state submitted September 30, 2015</p>

THIS AGREEMENT is between Oriel University ("Oriel" or "Oriel") and the Bill & Melinda Gates Foundation ("Foundation") and is effective as of the date of its approval. Each party to this Agreement may be referred to individually as a "Party" and together as the "Parties". As a condition of this grant, the Parties enter into this Agreement by having their authorized representatives sign below.

BILL & MELINDA GATES FOUNDATION ORIEL UNIVERSITY

[Signature] *[Signature]*
Senior Manager, M&D Fund Dean, Faculty of Medicine
November 12, 2015 November 12, 2015

Bill & Melinda Gates Foundation Oriel University
1000 L Street, N.E. 1100 St. John's Ave.
Washington, DC 20002-4299 St. John's, NL A1B 0X9

Prof. Dr. P. Mordeir
November 12, 2015

4-page concept note

Advantages

- Open communication
- First line information
- Creates new funding opportunities
- Flexibility

Do's

- Share material to the wider public
- Pitch the impact

Disadvantages

- Growing funding body
- Advice does not always guarantees funds
- Re-orienting research

Don'ts

- (No) PhD scholarship
- (No) capacity building

Zelege Mekonnen (2014)




LATEST NEWS

Johnson & Johnson Secures a Top Spot on the 2016 Access to Medicine Index

Pilot study Daniel dana (2015)

BILL & MELINDA GATES foundation (2017)



Scholarship Daniel Dana (2016)

Johnson & Johnson
FOUNDATION
(2019)



AI4
NTD

PhD student Peter Ward (2020)



World Health Organization



WHO Collaborating Centre for
Monitoring of Anthelmintic Drug Efficacy
for Soil-Transmitted Helminthiasis



Jozef Vercruyse (2009)
Ghent University



10 countries in Africa
and Asia **(2018 - 2022)**

THE **END** FUND | ENDING
NEGLECTED
DISEASES





World Health
Organization

Advantages

- Societal impact
- Little to no administration
- Freedom
- Creates research / funding opportunities

Disadvantages

- Huge time investment
- Politics
- Contact person is retiring
- Remote support

Grant for a long stay abroad

Schematic overview of measures related to international mobility

The regulations can be consulted [here](#).

Objective

This grant supports researchers who will be staying abroad for a longer period to perform advanced research or to specialize in specific research techniques. In this way, the FWO aims to increase the mobility of researchers and the international contacts between research groups.

International Coordination Action

Objective

With this funding channel, the FWO supports coordination activities of international collaborative associations. The funds are used for general scientific coordination and administrative management of the collaborative association (excluding the actual scientific research).

Postdoctoral Fellowships

Junior postdoctoral fellowship


The postdoctoral fellowships are intended to support researchers who have just completed a PhD and are developing an independent, international research career.

[» Read more](#)

PhD Fellowship fundamental research

Objective

A PhD Fellowship fundamental research allows young researchers to prepare a PhD, and to develop into independent scientists with a critical mindset. Fundamental research in the context of a PhD fellowship stands for challenging and innovative research (at PhD level).





Johnson & Johnson



virusos
SHARING MINDS, CHANGING LIVES



BILL &
MELINDA
GATES
foundation



fwo

4 quotes

- Best deals are made in the pub
- Dance with me to the end of love
- Sharing is caring
- Be a DJ in budget

Questions

Bruno.Levecke@UGent.be